Reporting from ESC 2024 – PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome
Reporting from ESC 2024 – PALISADE: Plozasiran Offers Hope for Treating Familial Chylomicronemia Syndrome New phase 3 data from plozasiran, a small interfering RNA therapy, presented at the European Society of Cardiology (ESC) Congress 2024 indicates there could be hope on the horizon for patients with familial chylomicronemia syndrome (FCS). The trial, named the PALISADE trial, found […]
Directly from ESC 2024 – Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a)
Directly from ESC 2024 – Kausik Ray, MD, MPhil: INTERASPIRE and the Expanding Knowledge Base for Lipoprotein(a) Few topics or biomarkers have garnered the same amount of attention for their association with cardiovascular risk in recent years as lipoprotein(a) [Lp(a)]. This trend continued at the European Society of Cardiology (ESC) Congress 2024, as the cardiology community and […]
Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM
Long-Term Data from ESC 2024 Reinforces Safety, Efficacy Profile of Mavacamten in oHCM New long-term data are highlighting the sustained benefits of mavacamten (Camzyos) among patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Presented during the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in the European Heart Journal, the latest data release from the MAVA-LTE trial offers […]
ESC 2024 – Brendon Neuen, MBBS, PhD: Expanding Evidence of Combination Therapy with GLP-1 RAs and SGLT2 Inhibitors
ESC 2024 – Brendon Neuen, MBBS, PhD: Expanding Evidence of Combination Therapy with GLP-1 RAs and SGLT2 Inhibitors Data from a systematic review and meta-analysis of placebo-controlled outcome trials of GLP-1 receptor agonists in type 2 diabetes is shedding further light on the effects of combination therapy with the class and SGLT2 inhibitors. Leveraging data […]
Directly from ESC 2024 – OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients
Directly from ESC 2024 – OCEANIC-AF: Asundexian Patients Have Nearly 4x Stroke, Embolism Risk vs Apixaban Patients The OCEANIC-AF trial has missed its primary endpoint, with use of asundexian nearly quadrupling the risk of stroke or systemic embolism compared with apixaban among high-risk patients with atrial fibrillation. Presented at the European Society of Cardiology (ESC) Congress 2024, […]
Newscasting from ESC 2024 – Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration
Newscasting from ESC 2024 – Rahul Aggarwal, MD: Sotagliflozin Benefit Grows with Increasing Diabetes Duration An analysis of the SCORED trial from the European Society of Cardiology (ESC) Congress 2024 highlights the effect of the SGLT1/2 inhibitor sotagliflozin (Inpefa) on heart failure outcomes based on diabetes duration. Results of the analysis, which were presented by Rahul Aggarwal, MD, of […]
ESC 2024 – FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease
ESC 2024 – FLOW: Semgalutide Provides Consistent CV Benefit Across Spectrum of Kidney Disease Use of semaglutide 1.0 mg (Ozempic) offers benefits on cardiovascular outcomes, regardless of baseline chronic kidney disease severity, according to an analysis of the FLOW trial presented at the European Society of Cardiology (ESC) Congress 2024. Presented by Kenneth Mahaffey, MD, professor […]
From ESC 2024: M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation
From ESC 2024: M-TEER Reduces Cardiovascular Risk, Improves Quality of Life in HF with Mitral Regurgitation Results of RESHAPE-HF2 suggest use of mitral transcatheter edge-to-edge repair (M-TEER) was more effective than optimal medical therapy alone for reducing cardiovascular event risk among patients with heart failure and moderate to severe mitral regurgitation ineligible for surgery. Presented […]
Reporting from ESC 2024: Single Blood Test Could Predict Cardiovascular, Stroke Risk in Women for Up to 30 Years
Reporting from ESC 2024: Single Blood Test Could Predict Cardiovascular, Stroke Risk in Women for Up to 30 Years A single blood test could predict cardiovascular for women for up to 3 decades, according to new research presented at the European Society of Cardiology (ESC) Congress 2024. The study, which leveraged high-sensitivity CRP (hsCRP), LDL cholesterol, […]
News Coverage from ESC 2024: In Women, History of Cancer Linked to Subclinical Atherosclerosis
News Coverage from ESC 2024: In Women, History of Cancer Linked to Subclinical Atherosclerosis New research presented at the European Society of Cardiology (ESC) Congress 2024 is making the case that clinicians should consider cancer as a risk factor for subclinical atherosclerosis. Presented by Sara Diaz Saravia, MD, of Mount Sinai Morningside, the study, which was a […]
